Kara X. Nghiem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kara X. Nghiem has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ananda Nole1 shared publication
- Arjun Kumar Menta
HEPIUS Innovation Laboratory, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
1 shared publication - Arushi Patel1 shared publication
- Ava Taylor1 shared publication
- Brendan Frederick1 shared publication
- Fujia Zheng1 shared publication
Latest Publications
- Open Access
- 21 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
An AI‑enabled, microscope‑integrated tool for decentralizing breast cancer diagnosis in Uganda: A mixed‑methods usability and workflow feasibility study (Preprint)
BACKGROUND Breast cancer is a leading cause of cancer morbidity and mortality worldwide, with disproportionately poor outcomes in low- and middle-income countries. In Uganda, delays between clinical presentation and diagnosis are driven by limited pathology capacity, long specimen transport times and weak referral systems. A task-shifting, low-cost diagnostic tool that brings cytology assessment closer to patients could reduce diagnostic delay and loss to follow-up. OBJECTIVE To evaluate and compare the usability and workflow feasibility of two Ekyaalo Diagnostics hardware form factors (V1 and V2), a low-cost AI-assisted platform for decentralized fine needle aspiration cytology slide digitization and remote pathology review across urban and rural health facilities in Uganda. It consists of a standard light microscope, off-the-shelf optical components and a smartphone application. METHODS We conducted a parallel, mixed-methods usability study to compare two hardware form factors across clinical settings in Uganda, in partnership with Makerere University, Mulago National Referral Hospital (NRH) and Mbarara Regional Referral Hospital (RRH). Study 1 evaluated V1 (smartphone adapter) at two tertiary hospitals (Mulago NRH and Mbarara RRH), while Study 2 evaluated V2 (eyepiece camera) across 11 rural and urban healthcare facilities spanning Health Centre IV–VII levels. Outcomes included System Usability Scale (SUS), ROI capture performance, Likert-scale usability measures and qualitative feedback on workflow integration and AI-assisted diagnosis. Non-parametric tests were used for group comparisons, and thematic analysis was used to analyze qualitative data from interviews and direct observations. RESULTS Both studies yielded encouraging results. In Study 1, mean SUS was 77.24 ± 17.18 indicated “good” usability and no statistically significant SUS differences across roles. Among 38 participants with capture data, mean regions of interest (ROI) captured was 6.39 ± 9.66, approximating routine review. AI outputs were viewed as supportive of the pathologist, rather than definitive. In Study 2, mean SUS was 66.59 ± 98.87, reflecting increased perceived complexity in rural contexts. Around 80% reported low confidence in acting on AI outputs without pathologist confirmation. Qualitative findings highlighted improved image quality and setup with V2 eyepiece camera but persistent constraints: shared microscopes, variable slide quality and a need for scanning the whole‑slide rather than sampling ROIs. CONCLUSIONS Ekyaalo Diagnostics demonstrated promising usability and strong acceptance among referral laboratory staff in Uganda. Ongoing iterative refinements that prioritize integration in rural settings, particularly by providing broader slide context and minimizing disruption to shared microscopes, are expected to enhance performance and acceptability. Given the similar challenges faced by low- and middle- income countries, Ekyaalo Diagnostics has the potential to reduce diagnostic delays in low-resource settings worldwide by supporting decentralized diagnostic workflows in low-resource settings.
- 21 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAn AI‑enabled, microscope‑integrated tool for decentralizing breast cancer diagnosis in Uganda: A mixed‑methods usability and workflow feasibility study (Preprint)
BACKGROUND Breast cancer is a leading cause of cancer morbidity and mortality worldwide, with disproportionately poor outcomes in low- and middle-income countries. In Uganda, delays between clinical presentation and diagnosis are driven by limited pathology capacity, long specimen transport times and weak referral systems. A task-shifting, low-cost diagnostic tool that brings cytology assessment closer to patients could reduce diagnostic delay and loss to follow-up. OBJECTIVE To evaluate and compare the usability and workflow feasibility of two Ekyaalo Diagnostics hardware form factors (V1 and V2), a low-cost AI-assisted platform for decentralized fine needle aspiration cytology slide digitization and remote pathology review across urban and rural health facilities in Uganda. It consists of a standard light microscope, off-the-shelf optical components and a smartphone application. METHODS We conducted a parallel, mixed-methods usability study to compare two hardware form factors across clinical settings in Uganda, in partnership with Makerere University, Mulago National Referral Hospital (NRH) and Mbarara Regional Referral Hospital (RRH). Study 1 evaluated V1 (smartphone adapter) at two tertiary hospitals (Mulago NRH and Mbarara RRH), while Study 2 evaluated V2 (eyepiece camera) across 11 rural and urban healthcare facilities spanning Health Centre IV–VII levels. Outcomes included System Usability Scale (SUS), ROI capture performance, Likert-scale usability measures and qualitative feedback on workflow integration and AI-assisted diagnosis. Non-parametric tests were used for group comparisons, and thematic analysis was used to analyze qualitative data from interviews and direct observations. RESULTS Both studies yielded encouraging results. In Study 1, mean SUS was 77.24 ± 17.18 indicated “good” usability and no statistically significant SUS differences across roles. Among 38 participants with capture data, mean regions of interest (ROI) captured was 6.39 ± 9.66, approximating routine review. AI outputs were viewed as supportive of the pathologist, rather than definitive. In Study 2, mean SUS was 66.59 ± 98.87, reflecting increased perceived complexity in rural contexts. Around 80% reported low confidence in acting on AI outputs without pathologist confirmation. Qualitative findings highlighted improved image quality and setup with V2 eyepiece camera but persistent constraints: shared microscopes, variable slide quality and a need for scanning the whole‑slide rather than sampling ROIs. CONCLUSIONS Ekyaalo Diagnostics demonstrated promising usability and strong acceptance among referral laboratory staff in Uganda. Ongoing iterative refinements that prioritize integration in rural settings, particularly by providing broader slide context and minimizing disruption to shared microscopes, are expected to enhance performance and acceptability. Given the similar challenges faced by low- and middle- income countries, Ekyaalo Diagnostics has the potential to reduce diagnostic delays in low-resource settings worldwide by supporting decentralized diagnostic workflows in low-resource settings.
- Open Access
A Novel Low-Profile Self-Expanding Biodegradable Percutaneous Heart Valve Frame That Grows with a Child
According to rough estimates, one in every 125 newborns born in the United States has a congenital cardiac abnormality that must be repaired. With the recent development of new biomaterials and innovative treatment methods, percutaneous cardiac valve replacement has been considered as an alternative to surgical procedures. While percutaneous heart valve replacement is a relatively new procedure with a few commercially available devices, the devices are not sufficiently low-profile, and do not grow with the child. To address this issue, a novel low-profile growing percutaneous pediatric heart valve frame made of two types of unique metallic biomaterials (supere lastic nitinol and biodegradable iron) has been developed through this study. The developed pediatric heart valve frame has an innovative mechanism that will expand its diameter by disconnecting biodegradable metals, enabling the growth of the device with the surrounding tissue in the cardiac space. The thermally treated iron wires show stable and gradual degradation characteristics, showing approximately 7.66% for both wires treated under 350 and 450 °C. Polymer-coated wires show a degradation range of 4.96 to 5.55% depending on the type of coating. Degradation test results show the predicted 9–23 months of degradation depending on the type of surface treatment (e.g., thermal treatment, polymer coating), which is a suitable range when compared with the theoretical arterial vessel remodeling process period in the human vascular system. Radial forces calculated by finite element analysis and measured by mechanical testing matched well, showing 5–6 N with a 20% diameter reduction considering the deployed valve frame in the heart. Biocompatibility study results demonstrated superior cell viability in thermally treated iron wires after 3 days of cell culture and showed rarely found platelets on the surface after 3-h blood exposure tests. Prototype devices were successfully fabricated using optimized advanced joining processes for dissimilar metallic materials such as nitinol and iron. This study represents the first demonstration of self-expanding and biodegradable percutaneous heart valve frames for pediatric patients that grow with a child.
Open AccessA Novel Low-Profile Self-Expanding Biodegradable Percutaneous Heart Valve Frame That Grows with a Child
According to rough estimates, one in every 125 newborns born in the United States has a congenital cardiac abnormality that must be repaired. With the recent development of new biomaterials and innovative treatment methods, percutaneous cardiac valve replacement has been considered as an alternative to surgical procedures. While percutaneous heart valve replacement is a relatively new procedure with a few commercially available devices, the devices are not sufficiently low-profile, and do not grow with the child. To address this issue, a novel low-profile growing percutaneous pediatric heart valve frame made of two types of unique metallic biomaterials (supere lastic nitinol and biodegradable iron) has been developed through this study. The developed pediatric heart valve frame has an innovative mechanism that will expand its diameter by disconnecting biodegradable metals, enabling the growth of the device with the surrounding tissue in the cardiac space. The thermally treated iron wires show stable and gradual degradation characteristics, showing approximately 7.66% for both wires treated under 350 and 450 °C. Polymer-coated wires show a degradation range of 4.96 to 5.55% depending on the type of coating. Degradation test results show the predicted 9–23 months of degradation depending on the type of surface treatment (e.g., thermal treatment, polymer coating), which is a suitable range when compared with the theoretical arterial vessel remodeling process period in the human vascular system. Radial forces calculated by finite element analysis and measured by mechanical testing matched well, showing 5–6 N with a 20% diameter reduction considering the deployed valve frame in the heart. Biocompatibility study results demonstrated superior cell viability in thermally treated iron wires after 3 days of cell culture and showed rarely found platelets on the surface after 3-h blood exposure tests. Prototype devices were successfully fabricated using optimized advanced joining processes for dissimilar metallic materials such as nitinol and iron. This study represents the first demonstration of self-expanding and biodegradable percutaneous heart valve frames for pediatric patients that grow with a child.